FAQ/Help |
Calendar |
Search |
Today's Posts |
05-13-2015, 01:33 PM | #11 | ||
|
|||
Junior Member
|
Quote:
All the best to everyone. |
||
Reply With Quote |
05-13-2015, 01:46 PM | #12 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
05-14-2015, 12:39 AM | #13 | ||
|
|||
Junior Member
|
Quote:
This is the only encouraging news I've heard lately concerning this disease and what is keeping me going. Just wanted to share some good news with everyone I'm as desperate as the next person for a cure or at the least stopping disease progression. We can all just hope and pray the end official report is as encouraging as the unofficial report I've been given. So far so good. All the best to everyone. |
||
Reply With Quote |
05-14-2015, 12:11 PM | #14 | ||
|
|||
Member
|
Use of Nilotinib Cancer Drug for Treatment of Parkinson’s, Alzheimer’s, Dementia
Hum. Mol. Genet. (2013)doi: 10.1093/hmg/ddt192 First published online: May 10, 2013 Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models Michaeline L. Hebron†, Irina Lonskaya† and Charbel E.-H. Moussa Abstract Parkinson’s disease is a movement disorder characterized by death of dopaminergic substantia nigra (SN) neurons and brain accumulation of α-synuclein. The tyrosine kinase Abl is activated in neurodegeneration.Here, we show that lentiviral expression of α-synuclein in the mouse SN leads to Abl activation (phosphorylation) and lentiviral Abl expression increases α-synuclein levels, in agreement with Abl activation in PD brains. Administration of the tyrosine kinase inhibitor nilotinib decreases Abl activity and ameliorates autophagic clearance of α-synuclein in transgenic and lentiviral gene transfer models. Subcellular fractionation shows accumulation of α-synuclein and hyper-phosphorylated Tau (p-Tau) in autophagic vacuoles in α-synuclein expressing brains, but nilotinib enhances protein deposition into the lysosomes. Nilotinib is used for adult leukemia treatment and it enters the brain within US Food and Drug Administration approved doses, leading to autophagic degradation of α-synuclein, protection of SN neurons and amelioration of motor performance. These data suggest that nilotinib may be a therapeutic strategy to degrade α-synuclein in PD and other α-synucleinopathies. [Show] Citation |
||
Reply With Quote |
05-14-2015, 06:39 PM | #15 | ||
|
|||
Senior Member
|
Girija mentions tyrosine kinase inhibitors.
If we assume that: - tyrosine kinase inhibitors are an effective treatment for PD. - any commercial drugs will take at least five years to get to market and even then be too expensive for many. Then it make sense to see if there are any natural substances with this property. A quick Google gives: - curcumin; - genistein (found in broad (fava) beans, soybeans, coffee, kudzu). Rick mentioned genistein back in 2012: http://neurotalk.psychcentral.com/sh...ight=genistein A quick sanity check: - epidemiological results suggest that coffee consumption is negatively associated with PD. - genistein crosses the BBB. John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
"Thanks for this!" says: |
05-14-2015, 09:25 PM | #16 | ||
|
|||
Member
|
Quote:
gynostemma tea should help PWP! As researchers continue to unravel the mysteries of AMPK, they have discovered four ways to boost the body’s AMPK activity: Exercise: AMPK activity increases with regular vigorous exercise.73 This beneficial effect of exercise on AMPK, however, may vanish in the elderly.5 Calorie Restriction: When you under eat, you create increased AMPK activity as cells sense a requirement to function more efficiently in the presence of diminished energy (food) intake. However, when normal food intake resumes, AMPK activity declines.74,75 Metformin: One of the drug metformin’s most beneficial mechanisms is to activate AMPK.76 This is one way it lowers elevated glucose.77 Unfortunately, most physicians only prescribe metformin for type II diabetes, making access to this drug difficult for most people. Some people also experience digestive upset in response to metformin and cannot take it.78 Botanical Extracts: Two natural agents (the Chinese herb Gynostemma pentaphyllum79 and trans -tiliroside derived from rose hips80) have been shown to activate AMPK. Each of these agents triggers different downstream metabolic benefits, and in one study, trans-tiliroside led to an even greater glucose-lowering effect than the AMPK-activating antidiabetic drug metformin.81 With these four documented methods of boosting AMPK signaling, there is no reason for aging humans to suffer the degenerative impact caused by loss of activated AMPK. As Gynostemma is a blood thinner be sure to talk with your MD before taking this herb. http://www.lef.org/Magazine/2014/SS/AMPK/Page-01?p=1 Last edited by zanpar321; 05-14-2015 at 10:23 PM. |
||
Reply With Quote |
01-08-2016, 02:43 AM | #17 | ||
|
|||
New Member
|
Since the formal report was released in Oct. 2015, the result was promising.
How about the Nilotinib tiral ii ? Does anyone kindly konw? |
||
Reply With Quote |
01-08-2016, 07:45 AM | #18 | ||
|
|||
Member
|
Quote:
sami, I saw the brief abstract released at the Neuroscience conference in Chicago last Oct. However, I haven't yet seen the full report. Do you have a link to an actual published report? |
||
Reply With Quote |
01-13-2016, 02:12 AM | #19 | ||
|
|||
Junior Member
|
I have an appointment at Georgetown Medstar UH, January 20. I'll ask about the trial but my neurologist isn't working directly with the trial and couldn't give me much information at my last visit the end of October. The doctor that was seeing me and working directly with the trial has left Georgetown and is now at the NIH. She was at GT on a fellowship. So I've lost my inside source but will see what, if anything I can find out this next appointment.
|
||
Reply With Quote |
01-26-2016, 01:36 AM | #20 | ||
|
|||
Junior Member
|
My last appointment at Georgetown Medstar movement disorder clinic I got some Information about the second phase of the Nilotinib trial. It's scheduled to start this summer and has funding. The funding is coming from foundations not Novartis. However Novartis is being approached to give the medications used in the trial. At the present time the trial will be testing the drug on stage l and stage ll PDers. It involves a lot of planning so my neuro said it could be delayed but he emphasized the funding was there. I don't know anything about the placebo group and how that will be handled. I go back again in March and he said he would give me all the current information he has on the trial at that time.
This is all I have at this time but will keep you posted about any information I'm told at my appointments. I'll ask about the placebo groups next visit. |
||
Reply With Quote |
"Thanks for this!" says: | anagirl (01-26-2016), badboy99 (01-26-2016), Drevy (02-02-2016), lab rat (01-27-2016), Nan Cyclist (01-26-2016), RooJr (01-27-2016), soccertese (01-26-2016), Tupelo3 (01-26-2016), zanpar321 (01-26-2016) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
My Article in Honor of Epilepsy Month, Published This month | Bipolar Disorder | |||
Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial | Parkinson's Disease | |||
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's D | Parkinson's Disease | |||
Safinamide..Merck Serono Announces 18-Month Safety and Efficacy Data Phase III Trial | Parkinson's Disease Clinical Trials | |||
CLINICAL TRIAL...Phase III Trial with Pimavanserin in Patients with PD Psychosis | Parkinson's Disease Clinical Trials |